GLP-1glp-1 receptor agonistssglt2 inhibitorsliver transplanttype 2 diabetes

GLP-1 users after liver transplant show lower mortality than SGLT2 inhibitor users

In 564 matched pairs drawn from a US network, GLP-1 receptor agonist use carried a hazard ratio of 0.622 for all-cause death.

By Maren Holt · Senior Reporter, GLP-1

Sep 28 20:00 ETSource: Metabolism: clinical and experimental

The wire

01Researchers emulated a target trial in TriNetX data covering 33,161 diabetic liver transplant recipients from 2015 to 2024, matching 564 pairs of new GLP-1 and SGLT2 inhibitor users.
02GLP-1 use was linked to lower ischemic heart disease (HR 0.721), heart failure (HR 0.502) and death, with no difference in infection or graft rejection, a common concern in transplant prescribing.
03The design is observational and cannot establish causality; the cirrhosis signal (HR 0.787) was borderline and inconsistent across propensity score models.

From the source

Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial
Metabolism: clinical and experimental · 2026 Sep 29 · Yen FS, Liao PL, Hung YM et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42810614/